Already have an account? Sign in instead.
You stay signed in for 30 days on this browser.
Continue with Google Continue with MicrosoftNo account yet? Create a free one.
We sent a six-digit code.
It expires in ten minutes, works once, and only in this browser. Five wrong tries void it. Send another code.
Your account is live and the Cloudflare checks are off for this browser.
14 Illinois opinions name it 2 courts 1899–2019 0 in the last five years
The cases below were cited by Illinois courts in a sentence that names this issue. Sides come from how each citing opinion treated the case (Syfertize flag on that citation), so a case can appear on both: that is where the law is contested. A red or yellow chip is the case's own overall treatment.
| Case | Followed | Cited |
|---|---|---|
Fisher v. Pelstringgreen2 sentences2015Fullington v. Pfizer, Inc., 720 F.3d 739, 745-47 (8th Cir. 2013) (reversing the trial court's dismissal of plaintiff's breach of implied warranty claim and strict- liability design-defect claim against generic manufacturers and remanding for reconsideration); Huck v. Wyeth, Inc., 850 N.W.2d 353, 356 (Iowa 2014) (reversing summary judgment for generic manufacturer and remanding for further proceedings on defendant's failure to update its label with "a stronger warning approved by the FDA"); Hassett, 74 A.3d at 215, 217 (holding that federal drug law does "not pre-empt claims based upon the mark 2015Fullington v. Pfizer, Inc., 720 F.3d 739, 745-47 (8th Cir. 2013) (reversing the trial court's dismissal of plaintiff's breach of implied warranty claim and strict- liability design-defect claim against generic manufacturers and remanding for reconsideration); Huck v. Wyeth, Inc., 850 N.W.2d 353, 356 (Iowa 2014) (reversing summary judgment for generic manufacturer and remanding for further proceedings on defendant's failure to update its label with "a stronger warning approved by the FDA"); Hassett, 74 A.3d at 215, 217 (holding that federal drug law does "not pre-empt claims based upon the mark | 3 | 3 |
Shirley Bell v. Pfizergreen2 sentences2015Fullington v. Pfizer, Inc., 720 F.3d 739, 745-47 (8th Cir. 2013) (reversing the trial court's dismissal of plaintiff's breach of implied warranty claim and strict- liability design-defect claim against generic manufacturers and remanding for reconsideration); Huck v. Wyeth, Inc., 850 N.W.2d 353, 356 (Iowa 2014) (reversing summary judgment for generic manufacturer and remanding for further proceedings on defendant's failure to update its label with "a stronger warning approved by the FDA"); Hassett, 74 A.3d at 215, 217 (holding that federal drug law does "not pre-empt claims based upon the mark 2015Fullington v. Pfizer, Inc., 720 F.3d 739, 745-47 (8th Cir. 2013) (reversing the trial court's dismissal of plaintiff's breach of implied warranty claim and strict- liability design-defect claim against generic manufacturers and remanding for reconsideration); Huck v. Wyeth, Inc., 850 N.W.2d 353, 356 (Iowa 2014) (reversing summary judgment for generic manufacturer and remanding for further proceedings on defendant's failure to update its label with "a stronger warning approved by the FDA"); Hassett, 74 A.3d at 215, 217 (holding that federal drug law does "not pre-empt claims based upon the mark | 3 | 3 |
Joyce Fullington v. Pfizer, Inc.green2 sentences2015Fullington v. Pfizer, Inc., 720 F.3d 739, 745-47 (8th Cir. 2013) (reversing the trial court's dismissal of plaintiff's breach of implied warranty claim and strict- liability design-defect claim against generic manufacturers and remanding for reconsideration); Huck v. Wyeth, Inc., 850 N.W.2d 353, 356 (Iowa 2014) (reversing summary judgment for generic manufacturer and remanding for further proceedings on defendant's failure to update its label with "a stronger warning approved by the FDA"); Hassett, 74 A.3d at 215, 217 (holding that federal drug law does "not pre-empt claims based upon the mark 2015Fullington v. Pfizer, Inc., 720 F.3d 739, 745-47 (8th Cir. 2013) (reversing the trial court's dismissal of plaintiff's breach of implied warranty claim and strict- liability design-defect claim against generic manufacturers and remanding for reconsideration); Huck v. Wyeth, Inc., 850 N.W.2d 353, 356 (Iowa 2014) (reversing summary judgment for generic manufacturer and remanding for further proceedings on defendant's failure to update its label with "a stronger warning approved by the FDA"); Hassett, 74 A.3d at 215, 217 (holding that federal drug law does "not pre-empt claims based upon the mark | 3 | 3 |
In Re Fosamax (Alendronate Sodium) Products Liability Litigationgreen2 sentences2015Fullington v. Pfizer, Inc., 720 F.3d 739, 745-47 (8th Cir. 2013) (reversing the trial court's dismissal of plaintiff's breach of implied warranty claim and strict- liability design-defect claim against generic manufacturers and remanding for reconsideration); Huck v. Wyeth, Inc., 850 N.W.2d 353, 356 (Iowa 2014) (reversing summary judgment for generic manufacturer and remanding for further proceedings on defendant's failure to update its label with "a stronger warning approved by the FDA"); Hassett, 74 A.3d at 215, 217 (holding that federal drug law does "not pre-empt claims based upon the mark 2015Fullington v. Pfizer, Inc., 720 F.3d 739, 745-47 (8th Cir. 2013) (reversing the trial court's dismissal of plaintiff's breach of implied warranty claim and strict- liability design-defect claim against generic manufacturers and remanding for reconsideration); Huck v. Wyeth, Inc., 850 N.W.2d 353, 356 (Iowa 2014) (reversing summary judgment for generic manufacturer and remanding for further proceedings on defendant's failure to update its label with "a stronger warning approved by the FDA"); Hassett, 74 A.3d at 215, 217 (holding that federal drug law does "not pre-empt claims based upon the mark | 3 | 3 |
Hassett v. Dafoegreen2 sentences2015Fullington v. Pfizer, Inc., 720 F.3d 739, 745-47 (8th Cir. 2013) (reversing the trial court's dismissal of plaintiff's breach of implied warranty claim and strict- liability design-defect claim against generic manufacturers and remanding for reconsideration); Huck v. Wyeth, Inc., 850 N.W.2d 353, 356 (Iowa 2014) (reversing summary judgment for generic manufacturer and remanding for further proceedings on defendant's failure to update its label with "a stronger warning approved by the FDA"); Hassett, 74 A.3d at 215, 217 (holding that federal drug law does "not pre-empt claims based upon the mark 2015Fullington v. Pfizer, Inc., 720 F.3d 739, 745-47 (8th Cir. 2013) (reversing the trial court's dismissal of plaintiff's breach of implied warranty claim and strict- liability design-defect claim against generic manufacturers and remanding for reconsideration); Huck v. Wyeth, Inc., 850 N.W.2d 353, 356 (Iowa 2014) (reversing summary judgment for generic manufacturer and remanding for further proceedings on defendant's failure to update its label with "a stronger warning approved by the FDA"); Hassett, 74 A.3d at 215, 217 (holding that federal drug law does "not pre-empt claims based upon the mark | 3 | 3 |
Theresa Huck v. Wyeth, Inc. D/B/A Wyeth Schwarz Pharma, Inc. and Pliva, Inc.green2 sentences2015Fullington v. Pfizer, Inc., 720 F.3d 739, 745-47 (8th Cir. 2013) (reversing the trial court's dismissal of plaintiff's breach of implied warranty claim and strict- liability design-defect claim against generic manufacturers and remanding for reconsideration); Huck v. Wyeth, Inc., 850 N.W.2d 353, 356 (Iowa 2014) (reversing summary judgment for generic manufacturer and remanding for further proceedings on defendant's failure to update its label with "a stronger warning approved by the FDA"); Hassett, 74 A.3d at 215, 217 (holding that federal drug law does "not pre-empt claims based upon the mark 2015Fullington v. Pfizer, Inc., 720 F.3d 739, 745-47 (8th Cir. 2013) (reversing the trial court's dismissal of plaintiff's breach of implied warranty claim and strict- liability design-defect claim against generic manufacturers and remanding for reconsideration); Huck v. Wyeth, Inc., 850 N.W.2d 353, 356 (Iowa 2014) (reversing summary judgment for generic manufacturer and remanding for further proceedings on defendant's failure to update its label with "a stronger warning approved by the FDA"); Hassett, 74 A.3d at 215, 217 (holding that federal drug law does "not pre-empt claims based upon the mark | 3 | 3 |
In re Reglan/Metoclopramide Litigationgreen2 sentences2015Fullington v. Pfizer, Inc., 720 F.3d 739, 745-47 (8th Cir. 2013) (reversing the trial court's dismissal of plaintiff's breach of implied warranty claim and strict- liability design-defect claim against generic manufacturers and remanding for reconsideration); Huck v. Wyeth, Inc., 850 N.W.2d 353, 356 (Iowa 2014) (reversing summary judgment for generic manufacturer and remanding for further proceedings on defendant's failure to update its label with "a stronger warning approved by the FDA"); Hassett, 74 A.3d at 215, 217 (holding that federal drug law does "not pre-empt claims based upon the mark 2015Fullington v. Pfizer, Inc., 720 F.3d 739, 745-47 (8th Cir. 2013) (reversing the trial court's dismissal of plaintiff's breach of implied warranty claim and strict- liability design-defect claim against generic manufacturers and remanding for reconsideration); Huck v. Wyeth, Inc., 850 N.W.2d 353, 356 (Iowa 2014) (reversing summary judgment for generic manufacturer and remanding for further proceedings on defendant's failure to update its label with "a stronger warning approved by the FDA"); Hassett, 74 A.3d at 215, 217 (holding that federal drug law does "not pre-empt claims based upon the mark | 3 | 3 |
Wyeth, Inc. v. Danny Weeks and Vicki Weeksred2 sentences2015Fullington v. Pfizer, Inc., 720 F.3d 739, 745-47 (8th Cir. 2013) (reversing the trial court's dismissal of plaintiff's breach of implied warranty claim and strict- liability design-defect claim against generic manufacturers and remanding for reconsideration); Huck v. Wyeth, Inc., 850 N.W.2d 353, 356 (Iowa 2014) (reversing summary judgment for generic manufacturer and remanding for further proceedings on defendant's failure to update its label with "a stronger warning approved by the FDA"); Hassett, 74 A.3d at 215, 217 (holding that federal drug law does "not pre-empt claims based upon the mark 2015Fullington v. Pfizer, Inc., 720 F.3d 739, 745-47 (8th Cir. 2013) (reversing the trial court's dismissal of plaintiff's breach of implied warranty claim and strict- liability design-defect claim against generic manufacturers and remanding for reconsideration); Huck v. Wyeth, Inc., 850 N.W.2d 353, 356 (Iowa 2014) (reversing summary judgment for generic manufacturer and remanding for further proceedings on defendant's failure to update its label with "a stronger warning approved by the FDA"); Hassett, 74 A.3d at 215, 217 (holding that federal drug law does "not pre-empt claims based upon the mark | 3 | 3 |
Helen Franzman v. Wyeth Inc.green2 sentences2015Fullington v. Pfizer, Inc., 720 F.3d 739, 745-47 (8th Cir. 2013) (reversing the trial court's dismissal of plaintiff's breach of implied warranty claim and strict- liability design-defect claim against generic manufacturers and remanding for reconsideration); Huck v. Wyeth, Inc., 850 N.W.2d 353, 356 (Iowa 2014) (reversing summary judgment for generic manufacturer and remanding for further proceedings on defendant's failure to update its label with "a stronger warning approved by the FDA"); Hassett, 74 A.3d at 215, 217 (holding that federal drug law does "not pre-empt claims based upon the mark 2015Fullington v. Pfizer, Inc., 720 F.3d 739, 745-47 (8th Cir. 2013) (reversing the trial court's dismissal of plaintiff's breach of implied warranty claim and strict- liability design-defect claim against generic manufacturers and remanding for reconsideration); Huck v. Wyeth, Inc., 850 N.W.2d 353, 356 (Iowa 2014) (reversing summary judgment for generic manufacturer and remanding for further proceedings on defendant's failure to update its label with "a stronger warning approved by the FDA"); Hassett, 74 A.3d at 215, 217 (holding that federal drug law does "not pre-empt claims based upon the mark | 3 | 3 |
In Re JAgreen2 sentences2019J.A., 316 Ill. 2018J.A. , 316 Ill. | 2 | 3 |
| Case | Negative | Cited |
|---|---|---|
| No negative-treatment citations attached to this issue in Illinois. Read the followed side critically anyway. | ||
| Case | Cited | Years |
|---|---|---|
People v. Washington
green
2 sentences2019A ‘truly persuasive demonstration of innocence’ would effectively reduce the idea to legal fiction.” Id. at 488 . ¶ 32 Despite Illinois generally recognizing freestanding claims of actual innocence, Illinois courts—and indeed, other courts throughout the country—have struggled with whether to recognize, and how to evaluate, such claims of actual innocence after a defendant has pleaded guilty. - 12 - No. 1-15-2994 ¶ 33 Some Illinois courts have expressed doubt as to whether a freestanding actual innocence claim may be brought after a valid and voluntary guilty plea, presuming that in order to p 2018A ‘truly persuasive demonstration of innocence’ would effectively reduce the idea to legal fiction.” Id. at 488 . ¶ 32 Despite Illinois generally recognizing freestanding claims of actual innocence, Illinois courts—and indeed, other courts throughout the country—have struggled with whether to recognize, and how to evaluate, such claims of actual innocence after a defendant has pleaded guilty. ¶ 33 Some Illinois courts have expressed doubt as to whether a freestanding actual innocence claim may be brought after a valid and voluntary guilty plea, presuming that in order to proceed on such a clai | 3 | 2018–2019 |
Norton v. Goodwine
neutral
2 sentences1971This is an even stronger presumption in those instances where the will was apparently executed in due form and the signatures are admitted to be genuine, Norton v. Goodwine, 310 Ill. 490 .” It is well-settled law in this State that execution of a will may be sufficiently proved where one attesting witness testified positively to the requisites of the execution when the other witness does not recall or deny his compliance with the statutory requisites. 1960Norton v. Goodwine, 310 Ill. 490 . | 2 | 1960–1971 |
Estate of Glogovsek v. Weck
green
1 sentence2012Otherwise, the closer a spouse is to his or her mate, the stronger a claim would be that the spouse is “excessively, improperly, and illegally influencing the testator.” Id. | 1 | 2012–2012 |
More v. More
neutral
2 sentences1974This is an even stronger presumption in those instances where the will was apparently executed in due form and the signatures are admitted to be genuine. [Citation.]” More v. More, 211 Ill. 268 , involved a case where the supreme court reversed a circuit court ruling that there was insufficient evidence to admit a will to probate. 1974This is an even stronger presumption in those instances where the will was apparently executed in due form and the signatures are admitted to be genuine. [Citation.]" More v. More, 211 Ill. 268 , involved a case where the supreme court reversed a circuit court ruling that there was insufficient evidence to admit a will to probate. | 1 | 1974–1974 |
In Re Estate of Koss
neutral
1 sentence1971(Loomis v. Campbell (1948), 333 Ill.App. 617 ; Estate of Koss (1967), 84 Ill.App.2d 59 .) An appeal from an order denying probate of a will is governed by the same principles as other civil appeals in reviewing alleged errors of the trial court. | 1 | 1971–1971 |
Loomis v. Campbell
neutral
1 sentence1971(Loomis v. Campbell (1948), 333 Ill.App. 617 ; Estate of Koss (1967), 84 Ill.App.2d 59 .) An appeal from an order denying probate of a will is governed by the same principles as other civil appeals in reviewing alleged errors of the trial court. | 1 | 1971–1971 |
Thomas v. Railroad Co.
green
1 sentence1899Ann. 173 .) Concerning this subject it is said in Thomas v. West Jersey Railroad Co. 101 U. S. 71 : “To hold that "this can be done is, in our opinion, to hold that any act done under a void contract makes all its parts valid, and that the more you do under a contract forbidden by law the stronger the claim to its enforcement in the courts.” We quote again from Central Transportation Co. v. Pullman Palace Car Co., as follows: “The view which this court has taken of the question presented by this branch of the case, and the only view which appears to us "consistent with legal principles, is as | 1 | 1899–1899 |
Counted by distinct opinions that both name this issue and are annotated to the section; sections every opinion cites regardless of issue are not filtered here, so read the counts against the total above.
Opinions by the citing court's state. A doctrine retained in one state and abandoned in another shows up here as a year span that stalls.